TRANSDERM-NITRO
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANSDERM-NITRO is a transdermal nitrate formulation delivered via extended-release film patch, approved in 1981 as an NDA small-molecule product. The generic mechanism is nitrate vasodilation, typically indicated for angina and cardiovascular conditions. This is a mature, legacy product with established clinical utility in chronic cardiovascular disease management.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive commercial positioning and rightsized team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRANSDERM-NITRO offers stable but limited career growth, as the product is in LOE-approaching phase with minimal innovation or expansion opportunity. Ideal for professionals seeking operational excellence, lifecycle management expertise, or roles in established markets rather than high-growth commercial environments.
Brand ManagerProduct Manager
Worked on TRANSDERM-NITRO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.